カテゴリ： MarketsandMarkets, 世界, 医療/バイオ

着床前遺伝学的検査（PGT）の世界市場予測（～2028）：処置別、技術別、製品別、用途別、サイクル種類別、エンドユーザー別、地域別

■ 英語タイトル：Preimplantation Genetic Testing Market by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート（データ管理コード：BT5411-23）■ 発行会社/調査会社：MarketsandMarkets
■ 商品コード：BT5411-23
■ 発行日：2023年10月17日
■ 調査対象地域：グローバル
■ 産業分野：バイオテクノロジー
■ ページ数：238
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[着床前遺伝学的検査（PGT）の世界市場予測（～2028）：処置別、技術別、製品別、用途別、サイクル種類別、エンドユーザー別、地域別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

"世界の着床前遺伝学的検査（PGT）市場は、2023年の7億米ドルから2028年には12億米ドルに達すると予測され、予測期間中の年平均成長率は11.4%" この市場の成長の主な原動力は、不妊治療クリニックや体外受精センターの増加、新規診断技術の開発に対する官民投資の活発化です。しかし、体外受精のための不利な政府規制や医療改革が着床前遺伝学的検査（PGT）市場の成長を抑制しています。

"着床前遺伝学的検査（PGT）市場において、予測期間中、技術別では次世代シーケンシングセグメントが最も高い市場シェアを占め"
タイプセグメントに基づき、着床前遺伝学的検査（PGT）市場はPCR、NGS、FISH、CGH、SNPに分類されます。DNAの塩基配列を決定する能力は、不妊治療におけるNGS技術の豊富な応用の道を開きました。NGSは、コスト削減、異なる結果（モザイク）を持つ胚を検出する優れた能力、欠失または重複セグメントを持つ染色体のような構造異常の検出を強化するなどの様々な利点を提供します。

"予測期間中、異数性アプリケーションセグメントが最も高いCAGRを占め"
アプリケーションに基づき、着床前遺伝学的検査（PGT）市場は、異数性、構造的染色体異常、単一遺伝子障害、X連鎖障害、HLAタイピング、性別識別に区分されます。異数性検出のための着床前遺伝子スクリーニングの使用は、胚の着床の可能性を高め、流産率を低下させ、染色体異常の子供を持つ可能性を減少させます。これらの利点が、異数性検出のための着床前遺伝学的検査（PGT）の需要を促進しています。

"着床前遺伝学的検査（PGT）市場において、予測期間中、地域別ではアジア太平洋セグメントが最も高い成長率を占め"
地域別に見ると、世界の着床前遺伝学的検査（PGT）市場は、北米、欧州、アジア太平洋地域、その他の地域に分類されます。アジア太平洋地域は予測期間中に高い成長率を示すと予想されています。アジア太平洋地域の新興国における急速な経済成長の結果として、中国やインドなどの地域の国々の可処分所得レベルは、アジア太平洋地域の着床前遺伝学的検査（PGT）市場に巨大な可能性を保持している過去10年間で顕著な増加を目撃しています。

供給側一次インタビューの内訳、企業タイプ別、役職別、地域別：
- 企業タイプ別 ティア1（50％）、ティア2（33％）、ティア3（17%）
- 役職別 Cレベル (17%)、ディレクターレベル (50%)、その他 (33%)
- 地域別 北米 (34%)、ヨーロッパ (35%)、アジア太平洋 (26%)、その他の地域 (5%)

主な企業は、Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), The Cooper Companies, Inc. (US), Abbott (US), Takara Bio Inc. (Japan), Qiagen (Germany), Vitrolife (Sweden), Oxford Nanopore Technologies Plc (UK), Oxford Gene Technology IP Limited (UK), Yikon Genomics (China), Shiva Scientific Company (India), Nanjing Superyears Gene Technology Co. Ltd. (China), Medicover Genetics (Germany), Medgenome (India), Fulgent Genetics (US), Invicta Genetics (Poland), Genea Limited (Australia), Scigene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co. Ltd. (China), Genemind Biosciences Co. Ltd. (China), Berry Genomics (China), and Bangkok Genomics Innovation (Thailand)などです。

調査範囲
この調査レポートは、着床前遺伝学的検査（PGT）市場を手技タイプ別（着床前遺伝学的スクリーニング、着床前遺伝学的診断）、技術別（次世代シーケンシング、ポリメラーゼ連鎖反応、蛍光in situハイブリダイゼーション、比較ゲノムハイブリダイゼーション、一塩基多型）、製品・サービス別（試薬・消耗品、機器、およびソフトウェアとサービス）、用途別（異数性、構造的染色体異常、単一遺伝子障害、x連鎖障害、HLAタイピング、および性別識別）、周期タイプ別（新鮮非ドナー、凍結非ドナー、新鮮ドナー、凍結ドナー）、エンドユーザー別（不妊治療クリニック、病院、診断ラボ、およびその他のエンドユーザー）、地域別（北米、欧州、アジア太平洋地域、およびその他の地域）に分析しています。着床前遺伝学的検査（PGT）市場の成長に影響を与える促進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、サービス、主要戦略、契約、パートナーシップ、合意などに関する洞察を提供します。着床前遺伝学的検査（PGT）市場に関連する新製品・サービスの発表、合併・買収、最近の動向。着床前遺伝学的検査（PGT）市場のエコシステムにおける今後の新興企業の競争分析を行っています。

レポート購入の主な利点
本レポートは、着床前遺伝学的検査（PGT）市場全体とサブセグメントの収益数の最も近い近似値に関する情報を提供することで、本市場の市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（世界的な不妊率の低下、新興国における不妊治療ツーリズムの台頭、不妊治療クリニックや体外受精センターの増加、新規診断技術の開発に対する官民投資の増加、母体年齢の上昇に伴う染色体異常の高リスク）、阻害要因（着床前遺伝学的検査（PGT）における手続きコストの高さ、体外受精手続きに対する政府の不利な規制や医療改革）の分析、着床前遺伝学的検査（PGT）市場の成長に影響を与える機会（医療インフラの改善、新興国における医療ツーリズムの増加、ひとり親や同性カップルによる不妊治療の選択肢の利用）、課題（着床前遺伝学的検査（PGT）を取り巻く社会倫理的な懸念、高齢化に伴う着床前遺伝学的検査（PGT）の手続き上の制限）などを分析しています。
- 製品開発/イノベーション：着床前遺伝学的検査（PGT）市場における今後の技術、研究開発活動、新製品・サービス開始に関する詳細な洞察を提供します。
- 市場開発：有利な市場に関する包括的な情報 - 本レポートでは、様々な地域における着床前遺伝学的検査（PGT）市場を分析しています。
- 市場の多様化：着床前遺伝学的検査（PGT）市場における新製品＆サービス、未開拓地域、最近の開発、投資に関する詳細情報を提供します。
- 競合評価：着床前遺伝学的検査（PGT）市場戦略におけるIllumina, Inc.（米国）、Thermo Fisher Scientific Inc.（米国）、Agilent Technologies, Inc.（米国）などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価しています。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 着床前遺伝学的検査（PGT）の世界市場：手技タイプ別
7 着床前遺伝学的検査（PGT）の世界市場：技術別
8 着床前遺伝学的検査（PGT）の世界市場：製品・サービス別
9 着床前遺伝学的検査（PGT）の世界市場：用途別
10 着床前遺伝学的検査（PGT）の世界市場：周期タイプ別
11 着床前遺伝学的検査（PGT）の世界市場：エンドユーザー別
12 着床前遺伝学的検査（PGT）の世界市場：地域別
13 競争状況
14 企業情報
15 付録

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 INCLUSIONS AND EXCLUSIONS 31
1.4 STUDY SCOPE 32
1.4.1 MARKETS CONSIDERED 32
FIGURE 1 PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION 32
1.4.2 YEARS CONSIDERED 33
1.4.3 CURRENCY CONSIDERED 33
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 2 RESEARCH DESIGN: PREIMPLANTATION GENETIC TESTING MARKET 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
FIGURE 3 PRIMARY SOURCES 38
2.1.2.1 Key industry insights 39
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primary interviews 40
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 41
2.2.1.1 Approach 1: Company revenue estimation approach 41
FIGURE 5 COMPANY REVENUE ESTIMATION APPROACH 41
2.2.1.2 Approach 2: Presentations of companies and primary interviews 41
2.2.1.3 Approach 4: Usage-based market estimation 42
FIGURE 6 MARKET SIZE ESTIMATION, BY PRODUCT UTILIZATION METHODOLOGY 42
2.2.1.4 Growth forecast 43
2.2.1.5 CAGR projections 43
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 43
2.2.2 TOP-DOWN APPROACH 43
FIGURE 8 TOP-DOWN APPROACH 44
2.3 MARKET ESTIMATION AND DATA TRIANGULATION 45
FIGURE 9 DATA TRIANGULATION METHODOLOGY 45
2.4 STUDY ASSUMPTIONS 46
2.5 RESEARCH LIMITATIONS 46
2.6 RISK ASSESSMENT 47
TABLE 1 RISK ASSESSMENT: PREIMPLANTATION GENETIC TESTING MARKET 47
2.7 RECESSION IMPACT ANALYSIS: PREIMPLANTATION GENETIC TESTING MARKET 47
3 EXECUTIVE SUMMARY 48
FIGURE 10 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 11 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 13 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 51
FIGURE 14 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 15 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 53
FIGURE 16 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 54
4 PREMIUM INSIGHTS 55
4.1 PREIMPLANTATION GENETIC TESTING MARKET OVERVIEW 55
FIGURE 17 RISING MATERNAL AGE AND DECLINING FERTILITY RATES TO DRIVE MARKET 55
4.2 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION (2023–2028) 56
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 56
4.3 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND COUNTRY (2021) 57
FIGURE 19 US AND REAGENTS AND CONSUMABLES SEGMENT COMMANDED LARGEST MARKET SHARE IN 2022 57
4.4 PREIMPLANTATION GENETIC TESTING MARKET: REGIONAL GROWTH OPPORTUNITIES 58
FIGURE 20 ASIA PACIFIC COUNTRIES TO GROW AT HIGHEST RATE DURING STUDY PERIOD 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: PREIMPLANTATION GENETIC TESTING MARKET 59
5.2.1 DRIVERS 60
5.2.1.1 Decline in fertility rates 60
TABLE 2 FERTILITY RATE, TOTAL (BIRTHS PER WOMAN), BY COUNTRY 60
5.2.1.2 Rise of fertility tourism in emerging economies 60
5.2.1.3 Increasing number of fertility clinics and IVF centers 61
5.2.1.4 Increasing public-private investments to develop novel diagnostic techniques 61
5.2.1.5 High risk of chromosomal abnormalities with advancing maternal age 62
TABLE 3 GLOBAL INCIDENCE RATE OF TRISOMY 62
5.2.2 RESTRAINTS 62
5.2.2.1 High procedural cost 62
5.2.2.2 Unfavorable government regulations and healthcare reforms for IVF procedures 63
5.2.3 OPPORTUNITIES 63
5.2.3.1 Improving healthcare infrastructure and rising medical tourism in emerging economies 63
5.2.3.2 Use of fertility treatments by single parents and same-sex couples 64
5.2.4 CHALLENGES 65
5.2.4.1 Socio-ethical concerns surrounding preimplantation genetic testing 65
5.2.4.2 Age-related procedural challenges 65
5.3 PRICING ANALYSIS 66
TABLE 4 INDICATIVE PRICING OF PREIMPLANTATION GENETIC TESTING PRODUCTS 66
TABLE 5 AVERAGE SELLING PRICE OF PREIMPLANTATION GENETIC TESTING SYSTEMS 66
5.4 VALUE CHAIN ANALYSIS 67
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 67
5.5 SUPPLY CHAIN ANALYSIS 68
FIGURE 23 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY OF PROMINENT COMPANIES 68
5.6 PORTER’S FIVE FORCES ANALYSIS 69
5.6.1 THREAT OF NEW ENTRANTS 69
5.6.2 THREAT OF SUBSTITUTES 69
5.6.3 BARGAINING POWER OF SUPPLIERS 69
5.6.4 BARGAINING POWER OF BUYERS 70
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.7 ECOSYSTEM MARKET MAP 70
FIGURE 24 ECOSYSTEM MARKET MAP: PREIMPLANTATION GENETIC TESTING MARKET 70
TABLE 6 ROLE IN ECOSYSTEM: PREIMPLANTATION GENETIC TESTING MARKET 71
FIGURE 25 KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET 72
5.8 REGULATORY ANALYSIS 72
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING PREIMPLANTATION GENETIC TESTING MARKET 72
5.8.1 NORTH AMERICA 73
5.8.1.1 US 73
5.8.1.2 Canada 73
5.8.2 EUROPE 74
5.8.2.1 UK 74
5.8.2.2 France 74
5.8.3 ASIA PACIFIC 74
5.8.3.1 Japan 74
5.8.3.2 India 74
5.9 PATENT ANALYSIS 75
5.9.1 PATENT TRENDS FOR PREIMPLANTATION GENETIC TESTING 75
FIGURE 26 PATENT TRENDS FOR PREIMPLANTATION GENETIC TESTING, JANUARY 2013–AUGUST 2023 75
5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS 76
FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PREIMPLANTATION GENETIC TESTING PATENTS, JANUARY 2013–AUGUST 2023 76
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.10.1 REVENUE SHIFT FOR PREIMPLANTATION GENETIC TESTING PRODUCTS 77
FIGURE 28 REVENUE SHIFT FOR PREIMPLANTATION GENETIC TESTING PRODUCTS 77
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024 78
TABLE 8 DETAILED LIST OF CONFERENCES AND EVENTS (JANUARY 2023–DECEMBER 2024) 78
5.12 TECHNOLOGY ANALYSIS 79
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 80
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 80
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PREIMPLANTATION GENETIC TESTING PRODUCTS 80
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PREIMPLANTATION GENETIC TESTING PRODUCTS (%) 80
5.13.2 BUYING CRITERIA 81
FIGURE 30 KEY BUYING CRITERIA FOR END USERS OF PREIMPLANTATION GENETIC TESTING MARKET 81
TABLE 10 KEY BUYING CRITERIA FOR END USERS OF PREIMPLANTATION GENETIC TESTING PRODUCTS 81
5.14 TRADE ANALYSIS 82
TABLE 11 IMPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION) 82
TABLE 12 EXPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION) 82
6 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE 83
6.1 INTRODUCTION 84
TABLE 13 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 84
6.2 PREIMPLANTATION GENETIC SCREENING 84
6.2.1 INCREASING MATERNAL AGE TO DRIVE MARKET 84
TABLE 14 PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC SCREENING, BY REGION, 2021–2028 (USD MILLION) 85
6.3 PREIMPLANTATION GENETIC DIAGNOSIS 85
6.3.1 RISING AWARENESS ABOUT CHROMOSOMAL ABNORMALITIES IN FETUSES TO DRIVE MARKET 85
TABLE 15 PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2021–2028 (USD MILLION) 86
7 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY 87
7.1 INTRODUCTION 88
TABLE 16 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 88
7.2 NEXT-GENERATION SEQUENCING 88
7.2.1 IMPROVED TECHNOLOGY FOR DETECTING STRUCTURAL ABNORMALITIES TO DRIVE MARKET 88
TABLE 17 PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 89
7.3 POLYMERASE CHAIN REACTION 89
7.3.1 INCREASED USAGE IN CLINICAL AND RESEARCH APPLICATIONS AND HIGH PREVALENCE OF GENETIC DISEASES TO DRIVE MARKET 89
TABLE 18 PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION) 90
7.4 FLUORESCENCE IN SITU HYBRIDIZATION 90
7.4.1 ADVANCES IN FLUORESCENCE MICROSCOPY AND DIGITAL IMAGING TO DRIVE MARKET 90
TABLE 19 PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 91
7.5 COMPARATIVE GENOMIC HYBRIDIZATION 91
7.5.1 LOW COST, LESS LABOR REQUIREMENT, AND ONGOING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 91
TABLE 20 PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 92
7.6 SINGLE-NUCLEOTIDE POLYMORPHISM 92
7.6.1 TIME-CONSUMING, EXPENSIVE, AND LABOR-INTENSIVE METHOD TO LIMIT MARKET 92
TABLE 21 PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2021–2028 (USD MILLION) 93
8 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE 94
8.1 INTRODUCTION 95
TABLE 22 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 95
8.2 REAGENTS AND CONSUMABLES 95
8.2.1 REAGENTS AND CONSUMABLES SEGMENT TO DOMINATE PREIMPLANTATION GENETIC TESTING MARKET 95
TABLE 23 PREIMPLANTATION GENETIC TESTING MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 96
8.3 INSTRUMENTS 96
8.3.1 ONGOING TECHNOLOGICAL ADVANCEMENTS AND INCREASING FERTILITY CLINICS TO DRIVE MARKET 96
TABLE 24 PREIMPLANTATION GENETIC TESTING MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 97
8.4 SOFTWARE AND SERVICES 97
8.4.1 RISING AWARENESS ABOUT DATA ANALYSIS TO DRIVE MARKET 97
TABLE 25 PREIMPLANTATION GENETIC TESTING MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2021–2028 (USD MILLION) 98
9 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION 99
9.1 INTRODUCTION 100
TABLE 26 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
9.2 ANEUPLOIDY 100
9.2.1 ANEUPLOIDY SEGMENT TO COMMAND LARGEST MARKET SHARE 100
TABLE 27 PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY REGION, 2021–2028 (USD MILLION) 101
9.3 STRUCTURAL CHROMOSOMAL ABNORMALITIES 102
TABLE 28 PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 29 PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 102
9.3.1 TRANSLOCATIONS 103
9.3.1.1 Rising incidence of translocation chromosomal abnormalities during IVF treatments to drive segment 103
TABLE 30 TRANSLOCATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 103
9.3.2 DELETIONS 104
9.3.2.1 Advancements in genetic testing to drive segment 104
TABLE 31 DELETIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
9.3.3 DUPLICATIONS 104
9.3.3.1 Rising cases of duplication of chromosomal abnormalities and increasing maternal age to drive segment 104
TABLE 32 DUPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 105
9.3.4 INVERSIONS 105
9.3.4.1 Risk of unexplained male‐factor infertility and multiple miscarriages to limit segment 105
TABLE 33 INVERSIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
9.4 SINGLE GENE DISORDERS 106
9.4.1 INCREASING AWARENESS ABOUT GENETIC TESTING TO DRIVE MARKET 106
TABLE 34 PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY REGION, 2021–2028 (USD MILLION) 107
9.5 X-LINKED DISORDERS 107
9.5.1 MEDICAL ADVANCEMENTS AND INCREASED RESEARCH ON GENETIC DISORDERS TO DRIVE MARKET 107
TABLE 35 PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY REGION, 2021–2028 (USD MILLION) 108
9.6 HLA TYPING 108
9.6.1 RISING NUMBER OF COUPLES WITH CHILDREN AFFECTED BY HEMATOLOGICAL DISEASES TO DRIVE MARKET 108
TABLE 36 PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY REGION, 2021–2028 (USD MILLION) 109
9.7 GENDER IDENTIFICATION 109
9.7.1 INCREASED FOCUS ON SEX DISCRIMINATION TO LIMIT MARKET 109
TABLE 37 PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY REGION, 2021–2028 (USD MILLION) 110
10 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE 111
10.1 INTRODUCTION 112
TABLE 38 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 112
10.2 FRESH NON-DONOR 112
10.2.1 HIGH RATES OF SUCCESSFUL PREGNANCY AMONG YOUNG WOMEN TO DRIVE MARKET 112
TABLE 39 PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONORS, BY REGION, 2021–2028 (USD MILLION) 113
10.3 FROZEN NON-DONOR 113
10.3.1 LONG-TERM STORAGE OF FROZEN EGGS AND EASY SCHEDULING TO DRIVE MARKET 113
TABLE 40 PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY REGION, 2021–2028 (USD MILLION) 114
10.4 FROZEN DONOR 114
10.4.1 BETTER AFFORDABILITY, HIGHER AVAILABILITY, AND EASIER IMPLANTATION TO DRIVE MARKET 114
TABLE 41 PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY REGION, 2021–2028 (USD MILLION) 115
10.5 FRESH DONOR 115
10.5.1 REAL-TIME GENETIC TESTING RESULTS AND EASY EMBRYO TRANSFER TO DRIVE MARKET 115
TABLE 42 PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY REGION, 2021–2028 (USD MILLION) 116
11 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER 117
11.1 INTRODUCTION 118
TABLE 43 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 118
11.2 FERTILITY CLINICS 118
11.2.1 HIGH SUCCESS RATE OF TREATMENT TO DRIVE MARKET 118
TABLE 44 PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY REGION, 2021–2028 (USD MILLION) 119
11.3 HOSPITALS 119
11.3.1 RISING NUMBER OF HOSPITALS FOR ART PROCEDURES TO DRIVE MARKET 119
TABLE 45 PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 120
11.4 DIAGNOSTIC LABORATORIES 120
11.4.1 IMPROVED CLINICAL EFFICACY AND INCREASED RESEARCH FUNDING TO DRIVE MARKET 120
TABLE 46 PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 121
11.5 OTHER END USERS 121
TABLE 47 PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 122
12 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION 123
12.1 INTRODUCTION 124
TABLE 48 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 124
12.2 NORTH AMERICA 125
12.2.1 NORTH AMERICA: RECESSION IMPACT 125
FIGURE 31 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT 126
TABLE 49 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 50 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 127
TABLE 51 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
TABLE 52 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 128
TABLE 53 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 54 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 55 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 130
TABLE 56 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 130
12.2.2 US 131
12.2.2.1 US to dominate North American preimplantation genetic testing market during forecast period 131
TABLE 57 US: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 132
TABLE 58 US: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 132
TABLE 59 US: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 133
TABLE 60 US: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 133
TABLE 61 US: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 62 US: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 134
TABLE 63 US: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 135
 
12.2.3 CANADA 135
12.2.3.1 Increasing government and non-government funding for curbing rising infertility rates to drive market 135
TABLE 64 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 136
TABLE 65 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 136
TABLE 66 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 137
TABLE 67 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 68 CANADA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 69 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 138
TABLE 70 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 139
12.3 EUROPE 139
12.3.1 EUROPE: RECESSION IMPACT 139
TABLE 71 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 72 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 140
TABLE 73 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141
TABLE 74 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 141
TABLE 75 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142
TABLE 76 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 77 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 143
TABLE 78 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 143
12.3.2 GERMANY 144
12.3.2.1 Low fertility rate and low cost of infertility treatment to drive market 144
TABLE 79 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 144
TABLE 80 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 145
TABLE 81 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 145
TABLE 82 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 83 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 84 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 147
TABLE 85 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 147
12.3.3 FRANCE 148
12.3.3.1 Rising government funding for genomics research and increasing median age for first-time pregnancies to drive market 148
TABLE 86 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 148
TABLE 87 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149
TABLE 88 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 149
TABLE 89 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
TABLE 90 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 91 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 151
TABLE 92 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 151
12.3.4 UK 152
12.3.4.1 Increasing IVF cycles and growing genetic abnormalities to drive market 152
TABLE 93 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 152
TABLE 94 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 153
TABLE 95 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 153
TABLE 96 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
TABLE 97 UK: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 98 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 155
TABLE 99 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 155
12.3.5 ITALY 156
12.3.5.1 Technological advancements in fertility treatment and decline in fertility rates among women to drive market 156
TABLE 100 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 156
TABLE 101 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157
TABLE 102 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 157
TABLE 103 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 158
TABLE 104 ITALY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 105 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 159
TABLE 106 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 159
12.3.6 SPAIN 160
12.3.6.1 Low cost of fertility treatment to drive market 160
TABLE 107 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 160
TABLE 108 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 161
TABLE 109 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 161
TABLE 110 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162
TABLE 111 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 112 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 163
TABLE 113 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 163
12.3.7 REST OF EUROPE 163
TABLE 114 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 164
TABLE 115 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 164
TABLE 116 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 165
TABLE 117 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 118 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 119 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 166
TABLE 120 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 167
12.4 ASIA PACIFIC 167
12.4.1 ASIA PACIFIC: RECESSION IMPACT 168
FIGURE 32 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT 169
TABLE 121 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 122 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 170
TABLE 123 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 171
TABLE 124 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 171
TABLE 125 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172
TABLE 126 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 127 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 173
TABLE 128 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 173
12.4.2 CHINA 174
12.4.2.1 Decreasing fertility rates and abolishment of one-child policy to drive market 174
TABLE 129 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 174
TABLE 130 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175
TABLE 131 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 175
TABLE 132 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 176
TABLE 133 CHINA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 134 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 177
TABLE 135 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 177
12.4.3 JAPAN 178
12.4.3.1 Rising adoption of IVF among infertile couples to drive market 178
TABLE 136 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 178
TABLE 137 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 179
TABLE 138 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 179
TABLE 139 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 180
TABLE 140 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 141 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 181
TABLE 142 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 181
12.4.4 INDIA 182
12.4.4.1 Rising medical tourism and increasing fertility clinics to drive market 182
TABLE 143 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 182
TABLE 144 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 183
TABLE 145 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 183
TABLE 146 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184
TABLE 147 INDIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 148 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 185
TABLE 149 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 185
12.4.5 REST OF ASIA PACIFIC 185
TABLE 150 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 186
TABLE 151 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186
TABLE 152 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 187
TABLE 153 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187
TABLE 154 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 155 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 188
TABLE 156 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 189
12.5 REST OF THE WORLD 189
12.5.1 LATIN AMERICA: RECESSION IMPACT 190
12.5.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 190
TABLE 157 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 190
TABLE 158 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 191
TABLE 159 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 191
TABLE 160 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 192
TABLE 161 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 162 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 193
TABLE 163 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 193
 
13 COMPETITIVE LANDSCAPE 194
13.1 OVERVIEW 194
13.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 194
TABLE 164 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET 194
13.3 REVENUE ANALYSIS OF KEY PLAYERS 195
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET 195
13.4 MARKET SHARE ANALYSIS 196
TABLE 165 DEGREE OF COMPETITION: PREIMPLANTATION GENETIC TESTING MARKET 196
13.5 COMPANY EVALUATION MATRIX OF KEY PLAYERS 197
13.5.1 STARS 197
13.5.2 EMERGING LEADERS 197
13.5.3 PERVASIVE PLAYERS 197
13.5.4 PARTICIPANTS 198
FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 198
13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES 199
13.6.1 PROGRESSIVE COMPANIES 199
13.6.2 STARTING BLOCKS 199
13.6.3 RESPONSIVE COMPANIES 199
13.6.4 DYNAMIC COMPANIES 199
FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UPS/SMES 200
13.7 COMPANY FOOTPRINT ANALYSIS 201
TABLE 166 OVERALL FOOTPRINT 201
TABLE 167 PRODUCT FOOTPRINT 202
TABLE 168 REGIONAL FOOTPRINT 203
13.8 COMPETITIVE BENCHMARKING 204
TABLE 169 DETAILED LIST OF KEY START-UPS/SMES IN PREIMPLANTATION GENETIC TESTING MARKET 204
13.9 COMPETITIVE SCENARIOS AND TRENDS 204
13.9.1 KEY PRODUCT LAUNCHES AND APPROVALS 204
TABLE 170 KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023 204
13.9.2 KEY DEALS 205
TABLE 171 KEY DEALS, 2020–2023 205
13.9.3 OTHER KEY DEVELOPMENTS 205
TABLE 172 OTHER KEY DEVELOPMENTS, 2020–2023 205

14 COMPANY PROFILES 206
14.1 KEY PLAYERS 206
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
14.1.1 ILLUMINA, INC. 206
TABLE 173 ILLUMINA, INC.: COMPANY OVERVIEW 206
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 207
14.1.2 THERMO FISHER SCIENTIFIC INC. 209
TABLE 174 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 209
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 210
14.1.3 AGILENT TECHNOLOGIES, INC. 212
TABLE 175 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 212
FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 213
14.1.4 REVVITY 215
TABLE 176 REVVITY: COMPANY OVERVIEW 215
FIGURE 39 REVVITY: COMPANY SNAPSHOT (2022) 216
14.1.5 THE COOPER COMPANIES, INC. 217
TABLE 177 THE COOPER COMPANIES, INC.: COMPANY OVERVIEW 217
FIGURE 40 THE COOPER COMPANIES INC.: COMPANY SNAPSHOT (2022) 218
14.1.6 ABBOTT 219
TABLE 178 ABBOTT: COMPANY OVERVIEW 219
FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2022) 220
14.1.7 TAKARA BIO INC. 221
TABLE 179 TAKARA BIO INC.: COMPANY OVERVIEW 221
FIGURE 42 TAKARA BIO INC.: COMPANY SNAPSHOT (2022) 222
14.1.8 QIAGEN 223
TABLE 180 QIAGEN.: COMPANY OVERVIEW 223
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2022) 224
14.1.9 VITROLIFE 225
TABLE 181 VITROLIFE.: COMPANY OVERVIEW 225
FIGURE 44 VITROLIFE: COMPANY SNAPSHOT (2022) 226
14.1.10 OXFORD NANOPORE TECHNOLOGIES PLC 228
TABLE 182 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW 228
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
14.2 OTHER PLAYERS 229
14.2.1 OXFORD GENE TECHNOLOGY IP LIMITED 229
14.2.2 YIKON GENOMICS 230
14.2.3 SHIVA SCIENTIFIC COMPANY 230
14.2.4 NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD. 231
14.2.5 MEDICOVER GENETICS 231
14.2.6 MEDGENOME 232
14.2.7 FULGENT GENETICS 232
14.2.8 INVICTA GENETICS 233
14.2.9 GENEA LIMITED 233
14.2.10 SCIEGENE CORPORATION 234
14.2.11 BIOARRAY S.L. 234
14.2.12 UNIMED BIOTECH (SHANGHAI) CO., LTD. 235
14.2.13 GENEMIND BIOSCIENCES CO., LTD. 235
14.2.14 BERRY GENOMICS 236
14.2.15 BANGKOK GENOMICS INNOVATION 236
15 APPENDIX 237
15.1 DISCUSSION GUIDE 237
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 242
15.3 CUSTOMIZATION OPTIONS 244
15.4 RELATED REPORTS 244
15.5 AUTHOR DETAILS 245

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 遠隔患者モニタリング（RPM）の世界市場予測（～2028）：製品別、エンドユーザー別、地域別
  • フローリング（床材）の世界市場予測（～2028）：素材別、エンドユーザー別、地域別
  • テレヘルス・テレメディスン（遠隔医療）の世界市場予測（～2028）：コンポーネント別、デリバリー別、用途別、エンドユーザー別、地域別
  • BIM（ビルディングインフォメーションモデリング）の世界市場予測（～2028）：製品別、展開別、プロジェクトライフサイクル別、用途別、エンドユーザー別、地域別
  • 固体酸化物形燃料電池（SOFC）の世界市場予測（～2028）：種類別、コンポーネント別、用途別、エンドユーザー別、地域別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(BT5411-23 )"着床前遺伝学的検査（PGT）の世界市場予測（～2028）：処置別、技術別、製品別、用途別、サイクル種類別、エンドユーザー別、地域別" (英文：Preimplantation Genetic Testing Market by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。